- <![CDATA[First-Line Danvatirsen Plus Pembrolizumab Fails to Improve Response Rates in Metastatic HNSCC]]><![CDATA[Danvatirsen in combination with pembrolizumab did not result in an ORR improvement vs pembrolizumab alone in first-line recurrent/metastatic HNSCC.]]>onclive · 2mo ago↗ source
- <![CDATA[Cumulative ADC Toxicities and Closing Reflections: Managing Edema, Fatigue, and Optimizing Long-Term Tolerability]]><![CDATA[This concluding segment addresses cumulative toxicities affecting long-term antibody-drug conjugate tolerability, with Hope Rugo, MD and Aaron Lisberg, MD discussing edema, fatigue, and st…onclive · 2mo ago↗ source
- <![CDATA[Dr Sznol on Optimal Treatment Sequencing in Melanoma]]><![CDATA[Mario Sznol, MD, discusses the challenges of determining whether to recommend adjuvant therapy for patients with melanoma based on current data. ]]>